Log in

9637 Alebund Pharmaceuticals (Jiangsu) Limited HKEX · China

Alebund Pharmaceuticals (Jiangsu) (9637) news

Alebund Pharmaceuticals (Jiangsu) Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 9637, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Alebund Pharmaceuticals (Jiangsu) news

We have not published a story on Alebund Pharmaceuticals (Jiangsu) yet. When there is news, it will appear here.

Questions about Alebund Pharmaceuticals (Jiangsu)

What is the ticker symbol of Alebund Pharmaceuticals (Jiangsu)?

Alebund Pharmaceuticals (Jiangsu) Limited trades under the ticker 9637 on HKEX.

Where is Alebund Pharmaceuticals (Jiangsu) listed?

Alebund Pharmaceuticals (Jiangsu) Limited is listed on HKEX.

Which country or territory is Alebund Pharmaceuticals (Jiangsu) listed under?

Our directory records Alebund Pharmaceuticals (Jiangsu) Limited under China.

What does Alebund Pharmaceuticals (Jiangsu) do?

Our directory classifies Alebund Pharmaceuticals (Jiangsu) Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Alebund Pharmaceuticals (Jiangsu)?

The ISIN recorded for Alebund Pharmaceuticals (Jiangsu) Limited is CNE100007QD0.

Does aibio.space cover Alebund Pharmaceuticals (Jiangsu)?

aibio.space lists Alebund Pharmaceuticals (Jiangsu) Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Alebund Pharmaceuticals (Jiangsu)?

Companies in our directory listed in the same country and business area as Alebund Pharmaceuticals (Jiangsu): Shanghai RAAS Blood Products Co., Zhejiang Hengtong Holding Co., LongBio Pharma (Suzhou) Co., Guangdong Vtr Bio-Tech Co., Shaanxi Micot Pharmaceutical Technology Co., Getein Biotech.

Investor discussion: Alebund Pharmaceuticals (Jiangsu)

Members talk about Alebund Pharmaceuticals (Jiangsu) (9637). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Alebund Pharmaceuticals (Jiangsu), newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) PROPOSED APPOINTMENT OF AUDITOR (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (3) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES AND (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING. Source

  2. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Alebund Pharmaceuticals (Jiangsu)'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR THE TREATMENT OF IgA NEPHROPATHY CLEARED BY THE U.S. FOOD AND DRUG ADMINISTRATION

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE LIST OF ELIGIBLE SECURITIES FOR SOUTHBOUND TRADING UNDER STOCK CONNECT AND IN THE HANG SENG COMPOSITE INDEX

  4. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  5. HKEXnews

    POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, AUGUST 14, 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR AP301 CAPSULES FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE RECEIVING DIALYSIS ACCEPTED FOR REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

  7. HKEXnews

    POSITIVE PROFIT ALERT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  8. HKEXnews

    Articles of Association

  9. HKEXnews

    AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  10. HKEXnews

    NOTICE OF EXTRAORDINARY GENERAL MEETING

  11. HKEXnews

    (1) PROPOSED APPOINTMENT OF AUDITOR (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (3) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES AND (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING

  12. HKEXnews

    FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

  13. HKEXnews

    Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

  14. HKEXnews

    Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST PARTICIPANT RANDOMIZED AND DOSED IN GLOBAL PHASE IIb MULTI-REGIONAL CLINICAL TRIAL OF AP306 FOR HYPERPHOSPHATEMIA IN PATIENTS RECEIVING MAINTENANCE HEMODIALYSIS

  16. HKEXnews

    ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

  17. HKEXnews

    Terms of Reference of the Strategy Committee

  18. HKEXnews

    Terms of Reference for the Nomination Committee of the Board of Directors

  19. HKEXnews

    Terms of Reference for the Remuneration and Appraisal Committee of the Board of Directors

  20. HKEXnews

    Terms of Reference for the Audit Committee of the Board of Directors

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:9637 on TradingView.

Listing details

Alebund Pharmaceuticals (Jiangsu) Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 9637, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Alebund Pharmaceuticals (Jiangsu) Limited
Ticker
9637
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007QD0
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.